- PR Newswire•3 days ago
Regulus will host a conference call and webcast on May 4, 2017 at 5:00 p.m. Eastern Time to discuss first quarter 2017 financial results. A live webcast of the call will be available online at www.regulusrx.com. To access the call, please dial (877) 257-8599 (domestic) or (970) 315-0459 (international) and refer to conference ID 12962939. Regulus Therapeutics Inc. (RGLS) is a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs. Regulus has leveraged its oligonucleotide drug discovery and development expertise to develop a well-balanced microRNA therapeutics pipeline complemented by a rich intellectual property estate to retain its leadership in the microRNA field. Regulus is advancing several programs in renal, hepatic and central nervous systems diseases, both independently and with our strategic alliance partners, Sanofi and AstraZeneca.
- GlobeNewswire•last month
DEADLINE APRIL 3: Khang & Khang LLP Announces Securities Class Action Lawsuit against Regulus Therapeutics, Inc. and Reminds Investors with Losses to Contact the Firm
IRVINE, Calif., March 31, 2017-- Khang & Khang LLP announces a class action lawsuit against Regulus Therapeutics, Inc.. Investors who purchased or otherwise acquired shares between January 21, 2016 and ...
- Accesswire•last month
SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Investing in Regulus Therapeutics, Inc. to Contact the Firm Before Imminent Lead Plaintiff Deadline
NEW YORK, NY / ACCESSWIRE / March 31, 2017 / Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Regulus Therapeutics, Inc. ("Regulus" or the "Company") ...
RGLS : Summary for Regulus Therapeutics Inc. - Yahoo Finance
Regulus Therapeutics Inc. (RGLS)
NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
|Bid||0.95 x 300|
|Ask||1.65 x 500|
|Day's Range||1.50 - 1.62|
|52 Week Range||0.94 - 6.25|
Trade prices are not sourced from all markets
|PE Ratio (TTM)||-1.00|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|